That increases Valeant’s offer to approximately $55 billion in cash and stock, up from the approximately $49 billion the company had offered two days prior.It is the second time Valeant increased its offer to Allergan stockholders after it first proposed an unsolicited merger with Allergan on 22 April.According to a statent from Valeant, the offer is subject to prompt good faith negotiation of a merger agreent between Valeant and Allergan, and shareholders will continue to be able to elect cash and/or Valeant stock, subject to proration.Pershing Square, Allergan’s largest shareholder with a 9.7 per cent stake, has agreed to elect only stock consideration and receive no cash consideration in the transaction and exchange its Allergan shares for Valeant shares at a 1.22659 exchange ratio, based on 29-May closing stock prices of Allergan and Valeant.
ACO extends deadline to apply for paediatric eyecare course
The Australian College of Optometry (ACO) has extended the application deadline for its 2025 Advanced Certificate in Children’s Vision (ACCV)...